On ****, Zai Lab rose over 8%, Hutchmed (China) rose nearly 5%, and Beigene rose about 3.6% according to Gelunhui. China Securities Co., Ltd. previously pointed out that many domestic innovative drug companies will release their latest clinical trial research results at ASCO conference in 2024. Overall, China's innovative drug companies cover various types of cancer drugs, such as monoclonal antibodies, bispecific antibodies, and ADCs, with innovative product designs and excellent clinical trial results, showing good clinical effects in various cancer treatments. We believe that China's innovative drug companies will continue to exert their efforts in the cancer field, and many products have shown the potential of being the best in class in cancer indications, with more clinical results to be expected in the future.
中概创新药企走高 再鼎医药涨超8%
Innovative drug companies in China are rising, with Zai Lab's stock up more than 8%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.